Objective: This study aimed to compare sublingual misoprosiol (as a new route of administration) to the vaginal route for pie-operative cervical priming in vacuum evacuation of first trimester missed abortion. Design: Prospective randomized clinical study Setting: Private practice in Domyal city during the period throughout March 2005 lo Septembcr2006. Methods: Eighty women with missed abortion (fetal death or blighted ova) of gcslational age < 2 weeks were randomized by a computer-generated model lo receive 400 \ig of misoprosiol (Misotac © SIGMA) either sublinguallj or vaginally 3 hours prior to manual vacuum aspiration (MVA) using the IPAS bivalve instrument with its plastic cannulas. The primary outcome measure was the degree of cervical dilatation, and secondary outcomes included the cervical resistance to dilate from 3-8mm (i.e. poor priming) indicated by the need lo use the traditional mclal Hegar's dilators instead of the plastic Karman cannulas, inlra-operative blood loss and incidence of pre-operalive side-effects. Results: There was no significant difference in the baseline cervical dilatation (sublingual: 7.6±l.3 mm; vaginal: 7.7 ± 0.73 mm), cervical resistance lo dilaic from 3 lo 8 mm with plastic Karman cannulas and need lo use mclal Hegar's dilators with some force (sublingual: 8 cases (20%); vaginal: 7 cases (17.5%). and total blood loss (sublingual-52.1±20.2 ml; vaginal: 48.3± 12.3ml). Pre-opcrative side-effects were also similar. Conclusions: Bolh sublingual and vaginal misoprosiol arc effective in cervical priming before surgical termination of pregnancy in the first trimester. Sublingual misoprosiol has the advantage of being more convenient to administer and may be more suitable for day surgery. Key Words: cervical priming-misoproslol-sublingual-vaginal . 
hospiuilizalion (3) . It might appear thai the incidence of severe morbidity has decreased recently in some of the countries in the developed world. Another more recent study, however, showed thai the incidences of 
INTRODUCTION
Surgical evacuation is currently the standard management for termination of pregnancies in the first trimester in many parts of the world. Il is considered to be safe and effective with a success rate of >95% O. However, it is associated with major morbidity in 1% of women and minor morbidity in 10% Laminaria tent has to be inserted for 12h and mifepristone has to be taken for 36-48h to have adequate cervical priming effect. Therefore they are less convenient for day-patients. Proslaglandin analogues are the cervical priming agents of choice and misoprostoi has been studied for this purpose^6" 8 ).
Both vaginal and oral administration were found to be useful* 
MATERIALS & METHODS
A total of 80 pregnant women diagnosed by ultrasound as missed abortion (fetal demise or blighted ovum) with gestational age 12 weeks or less.
The gestational age was established by a reliable (Table I ) . The findings at operation arc summarized in Table II . There was no significant difference in the baseline cervical dilatation between the (wo groups. The median dilatation for both groups was 8 mm. The blood loss was also comparable between the two groups.
Side-effects were similar in the two groups of women (Table  III) 
